WallStSmart
LEXX

Lexaria Bioscience Corp

NASDAQ: LEXX · HEALTHCARE · BIOTECHNOLOGY

$0.66
-4.34% today

Updated 2026-04-30

Market cap
$23.56M
P/E ratio
P/S ratio
64.01x
EPS (TTM)
$-0.47
Dividend yield
52W range
$0 – $2
Volume
0.2M

Lexaria Bioscience Corp (LEXX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+16.7%
Last 4 quarters
Revenue YoY growth
-88.5%
Most recent quarter
EPS YoY growth
+60.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+6.5%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+11.1%
2026-01-21
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-04-14$-0.06+50.0%$0.98$1.03+5.1%
2026-01-21$-0.10+41.2%$0.74$0.82+11.1%
2025-10-29$-0.14+9.7%$0.95$0.98+3.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-02-28$-0.12$-0.06+50.0%$20000.00-88.5%
2025-11-30$-0.17$-0.10+41.2%
2025-08-31$-0.16$-0.14+9.7%$174000.00+107.1%
2025-05-31$-0.16$-0.21-34.0%$174000.00+107.1%
2025-02-28$-0.16$-0.15+8.1%$174000.00+20.0%
2024-11-30$-0.12$-0.16-33.3%$183923.00+21.6%
2024-08-31$-0.11$-0.15-36.4%$84000.00+173.3%
2024-05-31$-0.10$-0.13-30.0%$84000.00
2024-02-29$-0.10$-0.06+40.0%$145000.00
2023-11-30$-0.11$-0.13-18.2%$151278.00
2023-08-31$-0.13$-0.12+7.7%$30741.00

Frequently asked questions

Has Lexaria Bioscience Corp beaten earnings estimates?
Lexaria Bioscience Corp has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +16.7% over the last 4 quarters.
How does LEXX stock react to earnings?
LEXX stock has moved an average of +6.5% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.
What is Lexaria Bioscience Corp's revenue growth rate?
Lexaria Bioscience Corp reported year-over-year revenue growth of -88.5% in its most recent quarter, with EPS growing +60.0% year-over-year.